SAGIMET BIOSCIENCES INC-A
SGMTNASDAQTrading Snapshot
- Day Range
- $9.64 – $9.85
- 52-Week Range
- $4.50 – $10.06
- Volume
- $2.87B
- Avg Volume
- $3.01B
- Shares Outstanding
- 32.6M
- Next Earnings
- Oct 22, 2026
Fundamentals Snapshot
- Annual Revenue
- $79M
- Last Q Revenue
- $19M
- P/E Ratio
- -7.4
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.89
- Dividend Yield
- 0.00%
Why Investors Own SGMT
- ✓High-growth profile — revenue up +9.0% YoY with expanding US Equity exposure.
- ✓Healthy economics — 33% gross margin and 6% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About SAGIMET BIOSCIENCES INC-A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Sagimet Biosciences Q2 EPS $(0.26) Misses $(0.25) Estimate
Sagimet Biosciences (NASDAQ:SGMT) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.25) by 4 percent. This is a 18.75 percent increase over losses of $(0.32) per share
Sagimet: A Look Ahead To Earnings And A Catalyst-Heavy H2 2026
Sagimet Biosciences is a catalyst-driven biotech, with value anchored to the upcoming U.S. Phase 3 denifanstat acne trial. Learn more on SGMT stock here.